Cargando…

Experience of a Strategy Including CYP2C19 Preemptive Genotyping Followed by Therapeutic Drug Monitoring of Voriconazole in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation

Many factors have been described to contribute to voriconazole (VCZ) interpatient variability in plasma concentrations, especially CYP2C19 genetic variability. In 2014, Hicks et al. presented data describing the correlation between VCZ plasma concentrations and CYP2C19 diplotypes in immunocompromise...

Descripción completa

Detalles Bibliográficos
Autores principales:	García-García, Irene, Dapía, Irene, Montserrat, Jaime, Martinez de Soto, Lucía, Bueno, David, Díaz, Lucía, Queiruga, Javier, Rodriguez Mariblanca, Amelia, Guerra-García, Pilar, Ramirez, Elena, Frías, Jesus, Pérez Martínez, Antonio, Carcas-Sansuan, Antonio J., Borobia, Alberto M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563584/ https://www.ncbi.nlm.nih.gov/pubmed/34744712 http://dx.doi.org/10.3389/fphar.2021.717932

Ejemplares similares

Health Care Workers’ Reasons for Choosing Between Two Different COVID-19 Prophylaxis Trials in an Acute Pandemic Context: Single-Center Questionnaire Study
por: Borobia, Alberto M, et al.
Publicado: (2021)

A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial
por: García, Irene García, et al.
Publicado: (2020)

Predictive engines based on pharmacokinetics modelling for tacrolimus personalized dosage in paediatric renal transplant patients
por: Prado-Velasco, Manuel, et al.
Publicado: (2020)

Acute Poisoning Readmissions to an Emergency Department of a Tertiary Hospital: Evaluation through an Active Toxicovigilance Program
por: Muñoz Romo, Raúl, et al.
Publicado: (2022)

Randomised multicentre clinical trial to evaluate voriconazole pre-emptive genotyping strategy in patients with risk of aspergillosis: vorigenipharm study protocol
por: Monserrat Villatoro, Jaime, et al.
Publicado: (2020)

Clinical Implementation of Pharmacogenetic Testing in a Hospital of the Spanish National Health System: Strategy and Experience Over 3 Years
por: Borobia, Alberto M., et al.
Publicado: (2017)

A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol
por: García-García, I., et al.
Publicado: (2021)

Outcomes and Costs of Poisoned Patients Admitted to an Adult Emergency Department of a Spanish Tertiary Hospital: Evaluation through a Toxicovigilance Program
por: Muñoz, Raúl, et al.
Publicado: (2016)

Melatonin in the Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers (MeCOVID): A Randomised Clinical Trial
por: García-García, Irene, et al.
Publicado: (2022)

Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell Transplants
por: Grau, Santiago, et al.
Publicado: (2015)

Preemptive interleukin-6 blockade in patients with COVID-19
por: Guillén, Lucía, et al.
Publicado: (2020)

Utility of Lymphocyte Transformation Test for Assisting Updated Roussel Uclaf Causality Assessment Method in Drug-Induced Liver Injury: A Case-Control Study
por: Rodríguez, Amelia, et al.
Publicado: (2022)

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation
por: Marks, David I, et al.
Publicado: (2011)

Identifying biomarkers of treatment response to ciclosporin in atopic dermatitis through multiomic predictive modelling: DERMATOMICS study protocol
por: Marín-Candón, Alicia, et al.
Publicado: (2023)

Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism
por: Shi, Hui-Yan, et al.
Publicado: (2010)

Incidence of Suspected Serious Adverse Drug Reactions in Corona Virus Disease-19 Patients Detected by a Pharmacovigilance Program by Laboratory Signals in a Tertiary Hospital in Spain: Cautionary Data
por: Ramírez, Elena, et al.
Publicado: (2020)

No changes in hemostasis after COVID-19–heterologous vaccination schedule: A subanalysis of the phase 2 CombiVacS study
por: Butta, Nora V., et al.
Publicado: (2023)

Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats
por: Lou, Yutao, et al.
Publicado: (2023)

A Phase I/II Dose-Escalation Multi-Center Study to Evaluate the Safety of Infusion of Natural Killer Cells or Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia: (RELEASE NCT04578210)
por: Pérez-Martínez, Antonio, et al.
Publicado: (2021)

A Phase II Randomized Multi-Center Study to Evaluate the Safety and Efficacy of Infusion of Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia (RELEASE NCT04578210)
por: Perez-Martinez, Antonio, et al.
Publicado: (2023)

An Acenocoumarol Dosing Algorithm Using Clinical and Pharmacogenetic Data in Spanish Patients with Thromboembolic Disease
por: Borobia, Alberto M., et al.
Publicado: (2012)

Impact of CYP2C19 Polymorphisms on Serum Concentration of Voriconazole in Iranian Hematological Patients
por: Ebrahimpour, Sholeh, et al.
Publicado: (2017)

Therapeutic drug monitoring and CYP2C19 genotyping guide the application of voriconazole in children
por: Chen, Xiaomin, et al.
Publicado: (2022)

Histoplasma capsulatum Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient Receiving Voriconazole Prophylaxis
por: Agrawal, Vaibhav, et al.
Publicado: (2020)

1733. Voriconazole Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplant: How Much Is Enough, Are Low Voriconazole Levels Associated With Opportunistic Infections, and What Are the Reasons for Discontinuation?
por: Hadjivassiliou, Giorgos, et al.
Publicado: (2019)

From non-preemptive to preemptive scheduling using synchronization synthesis
por: Černý, Pavol, et al.
Publicado: (2016)

Perioperative Comparison of Preemptive and Non-Preemptive Renal Transplant Recipients
por: Aytekin, Sami, et al.
Publicado: (2020)

A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis
por: Monserrat Villatoro, Jaime, et al.
Publicado: (2022)

CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy Adults
por: Muhareb, Amin, et al.
Publicado: (2023)

Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients
por: Li, Zi-Wei, et al.
Publicado: (2017)

CYP51A1 polymorphism and voriconazole-associated hepatotoxicity in children undergoing hematopoietic cell transplant
por: Takahashi, Takuto, et al.
Publicado: (2021)

Population pharmacokinetics of voriconazole and the role of CYP2C19 genotype on treatment optimization in pediatric patients
por: Hu, Lin, et al.
Publicado: (2023)

2566. Effect of CYP2C19 on Voriconazole Pharmacokinetics in Children with Malignancy or Inborn Errors in Immunity
por: Shoji, Kensuke, et al.
Publicado: (2023)

Advancing pharmacogenetic testing in a tertiary hospital: a retrospective analysis after 10 years of activity
por: Stewart, Stefan, et al.
Publicado: (2023)

1291. Safety of Isavuconazole Compared with Voriconazole as Primary Antifungal Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients
por: Bogler, Yael, et al.
Publicado: (2020)

Subcutaneous phaeohyphomycosis due to Phialemoniopsis ocularis successfully treated by voriconazole
por: Desoubeaux, Guillaume, et al.
Publicado: (2014)

A Phase II Randomized Multi-Center Study to Evaluate the Safety and Efficacy of Infusion of Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia (RELEASE NCT04578210)
por: Perez, Antonio, et al.
Publicado: (2022)

Improving Safety of Preemptive Therapy with Oral Valganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation
por: Barkam, Corinna, et al.
Publicado: (2012)

1601. Effect of Preemptive Rituximab Therapy on Epstein–Barr Reactivation in Allogenic Hematopoietic Stem Cell Pediatric Transplants
por: Catho, Gaud, et al.
Publicado: (2018)

Preemptive SARS patents
por: Brickley, Peg
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_thvkup062rm0j0dkflbpd5c95q